DDInter416 DDInter899
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C9
Clotrimazole {u} (Compound) upregulates {v} (Gene) PCK2
Clotrimazole {u} (Compound) is included by {v} (Pharmacologic Class) Azoles
Clotrimazole {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Clotrimazole (Compound) resembles Methadone (Compound)
Clotrimazole (Compound) resembles Diphenidol (Compound)
Clotrimazole (Compound) binds CYP2C9 (Gene)
Clotrimazole (Compound) upregulates PCK2 (Gene)
Clotrimazole (Compound) is included by Azoles (Pharmacologic Class)
Clotrimazole (Compound) causes Dermatitis bullous (Side Effect)